A Vaccine for Cancer: mRNA's Landmark Leap from COVID to Oncology

A personalized mRNA cancer vaccine finally proved its worth in the biggest trial of its kind. Moderna and Merck announced their Phase 3 INTerpath-001 trial hit its primary endpoint, showing that the vaccine intismeran plus Keytruda significantly reduced melanoma recurrence and spread compared to Keytruda alone in 1,137 high-risk patients. This is the first successful Phase 3 result for an mRNA-based personalized cancer therapy, marking a pivotal shift for the...